Osimertinib was the first drug to be approved for adjuvant treatment after complete tumour resection in adults with stage IB to IIIA non-small cell lung cancer (NSCLC).
from News Medical Medical Research News Feed https://ift.tt/3uxHUJI https://ift.tt/eA8V8J
from TechCrunch https://ift.tt/2Y8UAKQ
Home » TechCrunch » Osimertinib offers a hint of added benefit for NSCLC patients who have received adjuvant chemotherapy
Osimertinib offers a hint of added benefit for NSCLC patients who have received adjuvant chemotherapy
By Eresh • October 02, 2021 • https://techncruncher.blogspot.com/ TechCrunch • Comments : 0
Subscribe to:
Post Comments
(
Atom
)
Post a Comment